CAR T cells manufactured with interleukin-15 are expected to exhibit increased cytokine release upon antigen stimulation compared to those manufactured without it. This is because IL-15 promotes a more persistent, memory-like T cell phenotype with superior functional capacity for a robust and sustained anti-tumor response.